[Cost-minimization analysis of replacement therapy in the treatment of von Willebrand disease]

BACKGROUND: Replacement therapy with von Willebrand factor (VWF)/factor VIII (FVIII) concentrates represents an effective approach for patients with von Willebrand disease (VWD) who are unresponsive to desmopressin. However, various concentrates are available, with heterogeneous VWF content and VWF/...

Full description

Bibliographic Details
Main Author: Giancarlo Castaman
Format: Article
Language:English
Published: SEEd Medical Publishers 2016-06-01
Series:Farmeconomia: Health Economics and Therapeutic Pathways
Subjects:
Online Access:https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1249
id doaj-8dad0844692a494f8f8608f87d8a6c1a
record_format Article
spelling doaj-8dad0844692a494f8f8608f87d8a6c1a2020-11-25T02:56:06ZengSEEd Medical PublishersFarmeconomia: Health Economics and Therapeutic Pathways2240-256X2016-06-01172596510.7175/fe.v17i2.12491170[Cost-minimization analysis of replacement therapy in the treatment of von Willebrand disease]Giancarlo Castaman0Centro Malattie Emorragiche, Dipartimento Cardiotoracovascolare, Azienda Ospedaliero-Universitaria Careggi, FirenzeBACKGROUND: Replacement therapy with von Willebrand factor (VWF)/factor VIII (FVIII) concentrates represents an effective approach for patients with von Willebrand disease (VWD) who are unresponsive to desmopressin. However, various concentrates are available, with heterogeneous VWF content and VWF/FVIII ratio. AIM: To compare the costs associated to the replacement therapy with VWF/FVIII concentrates in Italy. METHODS: A cost-minimization analysis was performed to compare the pharmaceutical costs per patient of alternatives available for replacement therapy of VWD in the prospective of the Italian National Health Service. For each alternative the analysis calculated the number of vials, and relative costs, required to reach the target levels of VWF:RCo in patients who undergone to major surgery, minor surgery, spontaneous bleeding and prophylaxis. RESULTS: Haemate P® is associated with the lowest FVIII dosage, numbers of vials used and costs in all the clinical situations and at all the dosages considered. With Haemate P® the average costs in major surgery, minor surgery, spontaneous bleeding, and prophylaxis was € 710.94, € 592.45, € 473.96, and € 592.45, respectively. While the costs associated to Fanhdi®, Wilate®, and Wilfactin® was: € 1,309.28, € 1,071.23, € 952.20, and € 1,190.25; € 1,512.45, € 1,344.40, € 1,176.35, and € 1,344.40; € 3,814.09, € 3,269.22, € 3,269.22, and € 3,814.09. CONCLUSIONS: Treatment with Haemate P®, which presents a low FVIII content, allows to reach the target level of VWF:RCo with a lower number of vials and lower costs for the NHS. [Article in Italian]https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1249von willebrand diseasevon willebrand factorfactor viiictorfactor viii
collection DOAJ
language English
format Article
sources DOAJ
author Giancarlo Castaman
spellingShingle Giancarlo Castaman
[Cost-minimization analysis of replacement therapy in the treatment of von Willebrand disease]
Farmeconomia: Health Economics and Therapeutic Pathways
von willebrand disease
von willebrand factor
factor viiictor
factor viii
author_facet Giancarlo Castaman
author_sort Giancarlo Castaman
title [Cost-minimization analysis of replacement therapy in the treatment of von Willebrand disease]
title_short [Cost-minimization analysis of replacement therapy in the treatment of von Willebrand disease]
title_full [Cost-minimization analysis of replacement therapy in the treatment of von Willebrand disease]
title_fullStr [Cost-minimization analysis of replacement therapy in the treatment of von Willebrand disease]
title_full_unstemmed [Cost-minimization analysis of replacement therapy in the treatment of von Willebrand disease]
title_sort [cost-minimization analysis of replacement therapy in the treatment of von willebrand disease]
publisher SEEd Medical Publishers
series Farmeconomia: Health Economics and Therapeutic Pathways
issn 2240-256X
publishDate 2016-06-01
description BACKGROUND: Replacement therapy with von Willebrand factor (VWF)/factor VIII (FVIII) concentrates represents an effective approach for patients with von Willebrand disease (VWD) who are unresponsive to desmopressin. However, various concentrates are available, with heterogeneous VWF content and VWF/FVIII ratio. AIM: To compare the costs associated to the replacement therapy with VWF/FVIII concentrates in Italy. METHODS: A cost-minimization analysis was performed to compare the pharmaceutical costs per patient of alternatives available for replacement therapy of VWD in the prospective of the Italian National Health Service. For each alternative the analysis calculated the number of vials, and relative costs, required to reach the target levels of VWF:RCo in patients who undergone to major surgery, minor surgery, spontaneous bleeding and prophylaxis. RESULTS: Haemate P® is associated with the lowest FVIII dosage, numbers of vials used and costs in all the clinical situations and at all the dosages considered. With Haemate P® the average costs in major surgery, minor surgery, spontaneous bleeding, and prophylaxis was € 710.94, € 592.45, € 473.96, and € 592.45, respectively. While the costs associated to Fanhdi®, Wilate®, and Wilfactin® was: € 1,309.28, € 1,071.23, € 952.20, and € 1,190.25; € 1,512.45, € 1,344.40, € 1,176.35, and € 1,344.40; € 3,814.09, € 3,269.22, € 3,269.22, and € 3,814.09. CONCLUSIONS: Treatment with Haemate P®, which presents a low FVIII content, allows to reach the target level of VWF:RCo with a lower number of vials and lower costs for the NHS. [Article in Italian]
topic von willebrand disease
von willebrand factor
factor viiictor
factor viii
url https://journals.seedmedicalpublishers.com/index.php/FE/article/view/1249
work_keys_str_mv AT giancarlocastaman costminimizationanalysisofreplacementtherapyinthetreatmentofvonwillebranddisease
_version_ 1724714222566244352